What is Circle Pharma?
Founded in 2012, Circle Pharma operates at the intersection of computational biology and medicinal chemistry. The company has developed an indication-agnostic discovery engine specifically engineered to create cell-permeable macro-cyclic peptide therapeutics. Unlike traditional drug discovery methods, Circle Pharma's platform enables the targeting of complex protein-protein interactions, effectively expanding the druggable genome. This technological edge positions the company as a critical partner in the development of next-generation medicines, particularly in oncology and immunology. By focusing on structural biology and advanced computational modeling, the firm has established a robust pipeline that bridges the gap between academic research and clinical-stage therapeutic application.
How much funding has Circle Pharma raised?
Circle Pharma has raised a total of $204.8M across 4 funding rounds:
Series A
$3.8M
Series B
$45M
Series C
$66M
Series D
$90M
Series A (2016): $3.8M with participation from ShangPharma Investment Group, Ltd, Mission Bay Capital, and Pfizer Inc
Series B (2020): $45M led by ShangPharma Innovation Inc, The Column Group, Lifeforce Capital, Nextech Invest Ltd, and Berkeley Catalyst Fund
Series C (2021): $66M supported by The Column Group, Eli Lilly and Company, Euclidean Capital, Hartford HealthCare Endowment, Nextech Invest, Pavillion Capital, and Pandect Bioventures
Series D (2024): $90M featuring Euclidean Capital, Nextech Invest, and The Column Group
Key Investors in Circle Pharma
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, employing an edge-to-edge investment model that nurtures platforms from inception to exit.
Nextech Invest
Nextech Invest is a Zurich-based firm dedicated to accelerating advancements in precision medicine by identifying and nurturing transformative biotechnology companies during critical moments of scientific validation.
Euclidean Capital
Euclidean Capital is an investment firm that provides strategic backing to emerging companies, focusing on long-term value creation through disciplined capital allocation and industry expertise.
What's next for Circle Pharma?
With the successful closure of this major strategic investment, Circle Pharma is well-positioned to accelerate its clinical development programs and expand its internal discovery capabilities. The company's strategic roadmap likely involves scaling its computational infrastructure to handle increasingly complex therapeutic targets while simultaneously advancing its lead candidates through the regulatory pipeline. As the firm matures, the focus will shift toward establishing high-value partnerships with global pharmaceutical entities, leveraging its unique macro-cyclic peptide technology to solve critical unmet medical needs. The continued support from a sophisticated syndicate of life science investors provides the necessary runway to sustain long-term innovation and solidify its market position as a leader in precision medicine.
See full Circle Pharma company page
